Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethanol + paclitaxel is a combination used in two contexts: (1) as a component of paclitaxel formulations where ethanol serves as a solvent for the poorly water-soluble paclitaxel, and (2) as a therapeutic approach called percutaneous ethanol-paclitaxel combined therapy (PEPCT) where ethanol functions both as an ablative agent and as a carrier for paclitaxel. In formulations, paclitaxel has high solubility in ethanol (up to 40 mg/mL) compared to water (<0.1 μg/mL). As a therapeutic combination, PEPCT shows synergistic effects between ablation and chemotherapy, particularly for liver cancer treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethanol + paclitaxel.